Artikkeltips SLE

EULAR recommendations for women’s health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome.                               Andreoli L et al Ann Rheum Dis 2017;76:476-85 doi:10.1136/annrheumdis-2016-209770

Pregnancy outcome predictors in systemic lupus erythematosus: a systematic review and meta-analysis.                                                                                            Wind M et al. Lancet Rheumatol 2024;10:e667-683 doi: 10.1016/S2665-9913(24)00160-7                                                                                                              

Influence of disease activity and medications on offspring birth weight, pre-eclampsia and preterm birth in systemic lupus erythematosus: a population-based study.
Skorpen CG et al.  Ann Rheum Dis. 2018 Feb;77(2):264-269. doi: 10.1136/annrheumdis-2017-211641. Epub 2017 Nov 1. PMID: 29092851.

Disease Activity During Pregnancy and the First Year Postpartum in Women With Systemic Lupus Erythematosus.
Götestam Skorpen C et al. Arthritis Care Res (Hoboken). 2017 Aug;69(8):1201-1208. doi: 10.1002/acr.23102. Epub 2017 Jul 10. PMID: 27696790.

The efficacy of hydroxychloroquine in altering pregnancy outcome in women with antiphospholipid antibodies. Evidence and clinical judgement.                               Sciascia S et al.Thromb Haemost 2016;115:285-90 doi:10.1160/TH15-06-0491

Use of antimalarial drugs is associated with lower risk of preeclampsia in lupus pregnancy: a prospective cohort study.                                                                Saavedra MA et al. Int J Rheum Dis 2020;23:633-40 doi:10.1111/1756-185X.13830

Hydroxychloroquine in the pregnancies of women with lupus: a meta-analysis of individual participant data.                                                                                  Clowse MEB et al. Lupus Sci Med 2022;9:e000651 doi:10.1136/lupus-2021-000651